

## DAFTAR PUSTAKA

- Ailshul, M. D. (2012). Energy Balance and Obesity in Man. *Nutrition Today*, 10(5), 29–30. <https://doi.org/10.1097/00017285-197509000-00009>
- Apovian, C. (2016). Obesity: Definition, Comorbidities, Causes, and Burden. *Am J Manag Care*.22:S176-S185
- Badan Penelitian Pengembangan Kesehatan, 2019. (2018). *Laporan Nasional RISKESDAS*.
- Baretella O. (2014). Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents. *Elsevier :Life Sciences* 118 (2014) 206–21
- Barton, M., Carmona, R., Morawietz, H., Uscio, L. V, Goettsch, W., Hillen, H., ... Shaw, S. (2000). *Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo Evidence for a Regulatory Role of Endothelin*.
- Barton, M., Morawietz, H., Goettsch, W., Shaw, S., Lüscher, T. F., Haudenschild, C. C., Münter, K. (2012). Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo. *Hypertension*, 35(1), 329–336. <https://doi.org/10.1161/01.hyp.35.1.329>
- Barton, M., & Schiffrin, E. L. (2014). In memoriam: Wolfgang Kiowski, M.D. (1949–2012)--pioneer in clinical endothelin research. *Life Sciences*, 118(2), 91–96. <https://doi.org/10.1016/j.lfs.2014.08.011>
- Berghöfer A.(2008). Obesity prevalence from a European perspective: a systematic review. *BMC Public Health*.8():200.
- Bremnes T, Paasche JD, Mehлум A, Sandberg C, Bremnes B, and Attramadal H (2000). Regulation and intracellular trafficking pathways of the endothelin receptors. *J Biol Chem* 275:17596–17604.
- Cao X. Endothelin-1 mRNA in glomerular and epithelial cells of kidney. *Am J Physiol*; 265
- Chakker, H.A. (2015). Obesity Correlates With Glomerulomegaly But Is Not Associated With Kidney Dysfunction Early After Donation. *Transplant Direct* 1 (1). <https://doi.10.1097/TXD.0000000000000510>
- Charan, J., & Kantharia, N. (2013). How to calculate sample size in animal studies?

*Journal of Pharmacology and Pharmacotherapeutics*, 4(4), 303.  
<https://doi.org/10.4103/0976-500X.119726>

Chester, A. H., & Yacoub, M. H. (2014). The role of endothelin-1 in pulmonary arterial hypertension. *Global Cardiology Science and Practice*, 2014(2), 29.  
<https://doi.org/10.5339/gcsp.2014.29>

Comuzzie A. (2012). Novel Genetic Loci Identified for the Pathophysiology of Childhood Obesity in the Hispanic Population. *Plos One: Volume 7, Issue 12* : 51954

Connell, A (2017). Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. *Kidney International* 92:313-323.  
<http://dx.doi.org/10.1016/j.kint.2016.12.034>

Davenport A. (2016). Endothelin. *Pharmacological Rev* 68:357–418.  
<http://dx.doi.org/10.1124/pr.115.011833>

D'Agati, V. D., Chagnac, A., De Vries, A. P. J., Levi, M., Porrini, E., Herman-Edelstein, M., & Praga, M. (2016). Obesity-related glomerulopathy: Clinical and pathologic characteristics and pathogenesis. *Nature Reviews Nephrology*, 12(8), 453–471.  
<https://doi.org/10.1038/nrneph.2016.75>

De Mey et al. (2011). Long-lasting physiological antagonism of calcitonin gene-related peptide towards endothelin-1 in rat mesenteric arteries and human coronary arteries. *Eur J Pharmacol* 720:303–309.

Dhaun, N., Goddard, J., & Webb, D. (2006). The Endothelin System and Its Antagonism in Chronic Kidney Disease. *Journal of the American Society of Nephrology*, 17(4), 943–955. <https://doi.org/10.1681/asn.2005121256>

Dhaun, N., Webb, D. J., & Kluth, D. C. (2012). Endothelin-1 and the kidney - Beyond BP. *British Journal of Pharmacology*, 167(4), 720–731.  
<https://doi.org/10.1111/j.1476-5381.2012.02070.x>

Dimitrijevic, I et al. (2010). Increased Tissue Endothelin-1 and Endothelin B Receptor Expression from Patients with Giant Cell Arteritis. *American Academy of Ophthalmology*

Edwards et al (1997) Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. *Biochem J* 328:871–877

Eknoyan G. (2011). Obesity and Chronic kidney disease. *Nefrologia* 31(4):379-504. <https://doi.org/10.3265/Nefrologia.pre2011.May.10963>

Engin, A. (2017). *Obesity and Lipotoxicity* (Vol. 960). <https://doi.org/10.1007/978-3-319-48382-5>

ENHIS,(2009). Prevalence of overweight and obesity in children dan adolescents

- Eriksson, A. K. S., Van Harmelen, V., Stenson, B. M., Åström, G., Wåhlén, K., Laencikienė, J., & Rydén, M. (2009). Endothelin-1 stimulates human adipocyte lipolysis through the ET A receptor. *International Journal of Obesity*, 33(1), 67–74. <https://doi.org/10.1038/ijo.2008.212>
- Eroschenko, Victor P. (2008). DiFiore's Atlas of Histology With Functional Correlation 10<sup>th</sup>. Lippincott Williams & Wilkins: p355-373
- Evans NJ and Walker JW (2008a) Sustained Ca<sup>2+</sup> signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. *Can J Physiol Pharmacol* 86:526–535.
- Friedrich K., Miriam S., Sarah S. (2019). Perturbation of the Monocyte Compartment in Human Obesity. *Front Immunol* 10:1874. <https://doi.org/10.3389/fimmu.2019.01874>
- Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2017). Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. NCHS data brief, no 288. Hyattsville, MD: National Center for Health Statistics. *NCHS Data Brief, No 288. Hyattsville, MD: National Center for Health Statistics.*, (288), 2015–2016. Retrieved from <https://www.cdc.gov/nchs/products/databriefs/db288.htm>
- Herman, W. H., Emancipator, S. N., Rhoten, R. L. P., Simonson, M. S., William, H., Emancipator, S. N., ... Vascular, M. S. S. (2019). *Vascular and glomerular expression of endothelin-1 in normal human kidney.*
- Hruby, A., and Frank B. Hu. The Epidemiology of Obesity: A Big Picture. **2015**. *Pharmacoeconomics*. 2015 Jul; 33(7): 673–689. doi: 10.1007/s40273-014-0243-x
- Hunley, T. E., Ma, L.-J., & Kon, V. (2011). Scope and Mechanisms of Obesity-Related Renal Disease. *Curr Opin Nephrol Hypertens*, 19(3), 227–234. <https://doi.org/10.1097/MNH.0b013e3283374c09.Scope>
- Idris, I., Arsyad, A., Wardihan Sinrang, A., & Alwi, S. (2018). *The Profile of Endothelin-1 (Et-1), Receptor ETA, And Receptor ETB in Young and Adult Obese Wistar Rat.* 1(Sips 2017), 147–150. <https://doi.org/10.5220/0007334501470150>
- Idris, I., Sinrang, A. W., Arsyad, A., Alwi, S., & Sandira, M. I. (2019). *The rise of circulatory endothelin ( ET ) -1 and endothelin receptors ( ETA , ETB ) expression in kidney of obese wistar rat.* 11(2), 31–35.
- Jae HS, von Geldern TW, and Opgenorth TJ, et al. (2002) Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. *Clin Sci (Lond)* 103 (Suppl 48):112S–117S
- Johnstrom P, et al. (2005) Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. *Br J Pharmacol* 144:115–122.

- Kadouh, H. C., & Acosta, A. (2017). Current paradigms in the etiology of obesity. *Techniques in Gastrointestinal Endoscopy*, 19(1), 2–11. <https://doi.org/10.1016/j.tgie.2016.12.001>
- Kambham, N., Glen S. (2001). Obesity-related glomerulopathy: An emerging epidemic. 59(4):1498-1509. <https://doi.org/10.1046/j.1523-1755.2001.0590041498.x>
- Kawanabe&Nauli. (2016). Endothelin. *Systemic Sclerosis*, (September 2011), 155–171. [https://doi.org/10.1007/978-4-431-55708-1\\_10](https://doi.org/10.1007/978-4-431-55708-1_10)
- Kimura, S., Sakakibara, S., Nakajima, K., Kasuya, Y., Inoue, A., Ishikawa, T., ... Watanabe, T. X. (2006). Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. *Proceedings of the National Academy of Sciences*, 85(18), 6964–6967. <https://doi.org/10.1073/pnas.85.18.6964>
- Kohan, D. E. (2011). Regulation of Blood Pressure and Salt Homeostasis by Endothelin. <https://doi.org/10.1152/physrev.00060.2009>
- Kohan, D. E. (2013). *The 2013 Ernest Starling Award Role of collecting duct endothelin in control of renal function and blood pressure.* 84132. <https://doi.org/10.1152/ajpregu.00345.2013>
- Kopple, J. D., & Feroze, U. (2011). The effect of obesity on chronic kidney disease. *Journal of Renal Nutrition*, 21(1), 66–71. <https://doi.org/10.1053/j.jrn.2010.10.009>
- Kotelevtsev, Y., & Webb, D. J. (2001). *Endothelin as a natriuretic hormone : the case for a paracrine action mediated by nitric oxide.* 51, 481–488.
- Kovesdy, C. P., Furth, S. L., Zoccali, C., & World Kidney Day Steering Committee, on behalf of the W. K. D. S. (2017). Obesity and Kidney Disease: Hidden Consequences of the Epidemic. *Canadian Journal of Kidney Health and Disease*, 4, 2054358117698669. <https://doi.org/10.1177/2054358117698669>
- Kuc, R. E., Maguire, J. J., & Davenport, A. P. (2006a). Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ETA receptors in ETB-deficient mice. *Experimental Biology and Medicine*, 231(6), 741–745.
- Kuc, R. E., Maguire, J. J., & Davenport, A. P. (2006b). Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ETA receptors in ETB-deficient mice. *Experimental Biology and Medicine*, 231(6), 741–745.
- Ladabaum, U., Mannalithara, A., Myer, P. A., & Singh, G. (2010). Obesity , Abdominal Obesity , Physical Activity , and Caloric Intake in US Adults : 1988 to 2010. *The American Journal of Medicine*, 127(8), 717-727.e12. <https://doi.org/10.1016/j.amjmed.2014.02.026>
- Lakkis, J. I., & Weir, M. R. (2018). Obesity and Kidney Disease. *Progress in Cardiovascular Diseases*, 61(2), 157–167.

<https://doi.org/10.1016/j.pcad.2018.07.005>

Lehrke, I., Waldherr, R., Ritz, E., & Wagner, J. (2001). Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. *Journal of the American Society of Nephrology: JASN*, 12(11), 2321–2329. Retrieved from <http://jasn.asnjournals.org/content/12/11/2321.long%5Cnpapers2://publication/uuid/80E1030A-E8A7-4724-929E-C5BD974EAE60>

Levesque, R. J. R. (2018). WHO. *Encyclopedia of Adolescence*, pp. 2561–2565. [https://doi.org/10.1007/978-3-319-33228-4\\_447](https://doi.org/10.1007/978-3-319-33228-4_447)

Liang YJet al. (2012). Trends in general and abdominal obesity among Chinese children and adolescents 1993-2009. *Pediatr Obes*. 2012 Oct; 7(5):355-64.

Lindberg&Lamps. (2018). *Dignostic Pathology NORMAL HISTOLOGY*.

Lopez L et al. (2014). Histopathology of Chronic Kidney Disease of Unknown Etiology in Salvadoran Agriculture Communities. *Medicc Review* :Vol16, No.2

Maguire,J. J et al. (2015). Endothelin Receptors and Their Antagonists. *Seminars in Nephrology*, Vol 35, No 2, March 2015, pp 125–136

Mohamed Waleed, & Ahamed S Ashour. (2016). *Effect of obesity on Albino Rat kidney*. 4(3), 1–5. <https://doi.org/10.4172/2161-1017.1000>

NHLBI (National Heart, Lung and Blood Institute). (2000). *The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*. NIH Publication Number 00-4084

Nehus, E. (2018). Obesity and chronic kidney disease. *Current Opinion in Pediatrics*, 30(2), 241–246. <https://doi.org/10.1097/MOP.0000000000000586>

Nesti, D. R. (2015). *IMUNOREAKTIF INSULIN DAN GLUKAGON PADA PANKREAS TIKUS ( Rattus norvegicus ) OBESITAS*.

NHANES. (2019). *America’s Children and the Environment | Third Edition*

Niu, J et al. (2014). Association between endothelin-1/endothelin receptor A and inflammation in mouse kidneys following acute ischemia/reperfusion. *Molecular Medicine Report* <https://doi.org/10.3892/mmr.2014.3138>

Riaz, N., Wolden, S. L., Gelblum, D. Y., & Eric, J. (2016). *Endothelin and Endothelin Antagonists in Chronic Kidney Disease*. 118(24), 6072–6078. <https://doi.org/10.1002/cncr.27633>. Percutaneous

Ridwan,R., Rosdiana N., Haerani R., et al. (2019). Decreased Renal Function Induced by High-Fat Diet in Wistar Rat: The Role of Plasma Angiotensin Converting Enzyme 2 (ACE2). *Biomed Pharmacol J* 2019;12(3). <https://dx.doi.org/10.13005/bpj/1756>

- Riskesdas. (2013). Riset Kesehatan Dasar Kementerian RI. *Proceedings, Annual Meeting - Air Pollution Control Association*, 6. <https://doi.org/10.1016/j.procs.2013.12.001> Desember 2013
- Riskesdas. (2018). *RISKESDAS 2018* (Vol. 84). Retrieved from <http://ir.obihiro.ac.jp/dspace/handle/10322/3933>
- Ruesten A (2015). Trend in obesity prevalence in European adult cohort populations during follow-up since 1996 and their predictions to 2015. *PLoS One*. 2011; 6(11):e27455.
- Sajeda, D., Kumar, L. L., Peera, K., & Raju, K. T. (2018). *Restoration of Pathological changes in Kidney Tissue from Diet Induced Obese Rats Treated With Rinachantus Snasutus (linn) Kurtz Leaf Extract*. 7(4), 822–828. <https://doi.org/10.20959/wjpps20184-11205>
- Salim,H.M. (2018). The effect of High-fat Diet on Histological Changes of Kidney in Rats. *Biomolecular and Health Science Journal*.November 01 (02). e-journal.unair.ac.id/BHSJ
- Sandhu, J. S., Singla, M., Ahuja, A., Soni, A., & Chopra, P. (2004). *Renal Risks of Obesity*. 5(4), 335–338.
- Schneider, M. P., & Mann, J. F. (2014). *Endothelin antagonism for patients with chronic kidney disease: still a hope for the future*. 69–73. <https://doi.org/10.1093/ndt/gft339>
- Serra A., Romero R.,Lopez D. (2008). Renal injury in the extremely obese patients with normal renal function. *Kidney International*:Vol 73:947-955. <https://doi.org/10.1038/sj.ki.5002796>
- Sudhera, N., & Sidhu, S. (2012). Assessment of Obesity using various Anthropometric Variables among Young Adult Females of Amritsar ( Punjab ). *Human Biology Review*, 1(4), 365–375.
- Syndr, E. M., Maria, M., & Gene, P. (2016). Endocrinology & Metabolic Syndrome The Role of Prolactin in Men. *Endocrinology & Metabolic Syndrome*, 5(1), 1–6. <https://doi.org/10.4172/2161-1017.1000>
- Tobar, A., Ori, Y., Benchetrit, S., Milo, G., Herman-Edelstein, M., Zingerman, B., ... Chagnac, A. (2013). Proximal Tubular Hypertrophy and Enlarged Glomerular and Proximal Tubular Urinary Space in Obese Subjects with Proteinuria. *PLoS ONE*, 8(9), 1–9. <https://doi.org/10.1371/journal.pone.0075547>
- Tsuboi, N., Okabayashi, Y., Shimizu, A., & Yokoo, T. (2017). The Renal Pathology of Obesity. *Kidney International Reports*, 2(2), 251–260. <https://doi.org/10.1016/j.ekir.2017.01.007>
- Uzogara, S. G. (2017). Obesity Epidemic, Medical and Quality of Life Consequences: A Review. *Http://Www.Openscienceonline.Com/*, 5(1), 1. <https://doi.org/10.1016/j.opensci.2017.01.001>

- Vignon-Zellweger, N., Heiden, S., Miyauchi, T., & Emoto, N. (2012). Endothelin and endothelin receptors in the renal and cardiovascular systems. *Life Sciences*, *91*(13–14), 490–500. <https://doi.org/10.1016/j.lfs.2012.03.026>
- Virdis, A. (2016). Endothelial Dysfunction in Obesity: Role of Inflammation. *High Blood Pressure and Cardiovascular Prevention*, *23*(2), 83–85. <https://doi.org/10.1007/s40292-016-0133-8>
- Weil, B. R., Westby, C. M., Van Guilder, G. P., Greiner, J. J., Stauffer, B. L., & DeSouza, C. A. (2011). Enhanced endothelin-1 system activity with overweight and obesity. *American Journal of Physiology-Heart and Circulatory Physiology*, *301*(3), H689–H695. <https://doi.org/10.1152/ajpheart.00206.2011>
- Watts SW, Thakali K, Smark C, Rondelli C, and Fink GD (2007) Big ET-1 processing into vasoactive peptides in arteries and veins. *Vascul Pharmacol* 47:302–312
- Wendel M, Knels. (2006). Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. *J Histochem Cytochem*. 54:1193–1203.
- WHO. (2018). Obesity and Overweight.
- Wulfing P., Raihanatou Diallo. (2020). Expression of Endothelin-1, Endothelin-A, and Endothelin-B Receptor in Human Breast Cancer and Correlation with Long-Term Follow-Up. *American Association for Cancer Research*. 9, 4125-4131
- Yang, C., Li, L., Yang, L., Lu, H., Wang, S., & Sun, G. (2018). Anti-obesity and Hypolipidemic effects of garlic oil and onion oil in rats fed a high-fat diet. *Nutrition and Metabolism*, *15*(1), 4–11. <https://doi.org/10.1186/s12986-018-0275-x>
- Zanatta, C. M., Verionese, F. V., Da Silva Loreto, M., Sortica, D. A., Carpio, V. N., Eldeweiss, M. `2wecfrl. A., ... Canani, L. H. (2012). Endothelin-1 and endothelin A receptor immunoreactivity is increased in patients with diabetic nephropathy. *Renal Failure*, *34*(3), 308–315. <https://doi.org/10.3109/0886022X.2011.647301>
- Zarrati, M., E.Salehi.,E Razmpoosh. (2016). Relationship between leptin concentration and body fat with peripheral blood mononuclear cells cytokines among obese and overweight adults. *Irish Journal of Medical Science* 186,133-142
- Zellweger, N.V. (2012). Endothelin and endothelin receptors in the renal and cardiovascular systems. Elsevier Inc. Open access. <http://dx.doi.org/10.1016/j.lfs.2012.03.026>



HARI 40				HARI 50				HARI 60				Hari 63					
IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL
25.85936	295.168	273	22	25.63862	294.319801	291	22	27.32908	300.6448	F1	301	22	28.26822	304.0465	F1		
32.71785	319.2281	318	22	29.86476	309.660314	325	22	30.52216	311.9137	F2	332	22	31.17956	314.135	F2		
29.78354	309.3867	325	22.5	28.53224	304.982304	343	22.5	30.11248	310.5063	F3	348	22.5	30.55144	312.0063	F3		
30.77421	312.7837	309	21.5	31.0916	313.846806	303	21.5	30.48788	311.8042	F4	308	21.5	30.99098	313.5082	F4		
33.79765	322.6985	317	22.5	27.8299	302.46158	335	22.5	29.41015	308.0757	F5	350	22.5	30.72702	312.6023	F5		
27.9177	302.779	330	23	27.12254	299.87296	357	23	29.34166	307.8298	F6	365	23	29.99918	310.1099	F6		
27.53482	301.4106	267	21.5	26.86556	298.943965	274	21.5	27.5699	301.5314	F7	279	21.5	28.073	303.3526	F7		
31.31411	314.6004	300	22	28.17431	303.709724	317	22	29.77085	309.3357	F8	324	22	30.42825	311.5938	F8		
30.25	311.0144	267	21	28.83058	306.061678	277	21	29.91038	309.8321	F9	281	21	30.3423	311.3149	F9		
31.57238	315.4697	283	21.5	28.47548	304.794007	305	21.5	30.68912	312.488	F10	312	21.5	31.39346	314.8582	F10		
29.01873	306.7328	265	21.5	26.66432	298.196414	277	21.5	27.87176	302.6267	F11	279	21.5	28.073	303.3526	F11		
28.97858	306.5768	299	22	28.08039	303.372231	315	22	29.58302	308.6844	F12	316	22	29.67693	309.0104	F12		
				309.82				29.3832	308.60				29.97528	310.53			

HARI 40				HARI 50				HARI 60				Hari 63					
IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL	BB	PJ	IR	IL
27.62583	301.7493	249	21.5	25.0544	292.076034	253	21.5	25.45688	293.6302	C1	259	21.5	26.0606	295.9309	C1		
27.25	300.3835	235	20.5	27.27761	300.477348	243	20.5	28.20621	303.8457	C2	219	20.5	25.42041	293.504	C2		
29.0792	306.9308	317	22.5	27.8299	302.46158	333	22.5	29.23457	307.462	C3	340	22.5	29.84911	309.5993	C3		
25.65812	294.4011	257	22	24.13599	288.459635	269	22	25.26296	292.8767	C4	269	22	25.26296	292.8767	C4		
29.20736	307.3736	332	23	27.28692	300.476939	341	23	28.02663	303.1652	C5	346	23	28.43758	304.6383	C5		
29.37048	307.9585	297	22	27.89256	302.694979	311	22	29.20736	307.3736	C6	312	22	29.30128	307.7023	C6		
30.78974	312.8288	333	22.5	29.23457	307.461974	351	22.5	30.81481	312.8994	C7	356	22.5	31.25377	314.3767	C7		
28.073	303.3526	296	22	27.79865	302.355212	288	22	27.04733	299.6091	C8	295	22	27.70473	302.0147	C8		
26.58116	297.9006	241	22	22.63336	282.350782	243	22	22.82119	283.1289	C9	250	22	23.47859	285.8192	C9		
21.93816	279.4524	205		#DIV/0!				#DIV/0!		C10			#DIV/0!		C10		
27.42684	301.0165	255	22	23.94816	287.71016	261	22	24.51165	289.947	C11	271	22	25.45079	293.6	C11		
#DIV/0!	301.21			#DIV/0!	296.652464			#DIV/0!	297.6838				#DIV/0!	300.459			

**INDEKS**  
 Röhrer index  $\{ \text{Body weight (g)} / \text{Naso-anal length (cm)} \}^3 \times 10^3$  Value > 30  
 Lee index  $\{ \text{Body weight (g)} \}^{1/3} / \{ \text{Naso-anal length (cm)} \} \times 10^3$  Value > 300  
 TM index  $\text{Body weight (g)} / \text{Naso-anal length (cm)}^{-2.833} \times 10^5$  Value > 55

**RUMUS**  
 #DIV/0!  
 #DIV/0!  
 #DIV/0!  
 #DIV/0!

**OBSITAS**  
 Value > 30  
 Value > 300  
 Value > 55

NO	KODE	BG	Glomerulus										CGKakoMean	CGKakoMedian	CGKakoModus
			1	2	3	4	5	6	7	8	9	10			
1	C1	1.5399	0	0	0	1	1	2	0	1	0.6	0	0		
2	C2	1.3011	1	0	0	1	0	0	0	0	0.2	0	0		
3	C3	2.1001	0	0	0	0	0	0	0	0	0	0	0		
4	C4	1.5992	0	0	0	0	0	0	0	0	0	0	0		
5	C5	1.1441	0	0	0	0	0	0	0	0	0	0	0		
6	C6	1.2709	0	1	0	0	0	1	0	0	0.2	0	0		
7	C7	1.7522	0	1	1	0	0	0	1	1	1.2	1.02	0.822		
8	C8	1.2899	3	3	2	2					0.2	0	0		
9	C9	1.0994	0	0	0	1	0	1	0	1	0	0	0		
10	C10										0.4	0	0		
11	C11	1.2629	0	1	1	0	2	0	0	0	0	0	0		
12	C12														

  

NO	KODE	BG	Glomerulus										FGKakoMean	FGKakoMedian	FGKakoModus
			1	2	3	4	5	6	7	8	9	10			
1	C1	1.5467	2	2	1	0	0	0	1	1	0.7	1	0		
2	C2	1.412	2	1	2	2	2	2	2	1	1.8	2	2		
3	C3	1.8468	0	0	0	1	0	1	0	0	0.2	0	0		
4	C4	1.3551	0	0	1	0	0	1	0	1	0.4	2	0		
5	C5	1.3882	0	0	1	0	1	0	1	0	0.2	0	0		
6	C6	1.2479	0	0	1	1	1	0	1	0	0.4	0	0		
7	C7	1.6903	0	0	1	1	2	0	1	0	0.6	1	0		
8	C8	1.1666	0	0	1	0	0	0	0	0	0.2	0.2	0.2		
9	C9	0.9653	0	0	0	0	0	0	0	0	0	0	0		
10	C10										0	0	0		
11	C11	1.2049	0	1	1	0	1	0	1	0	0.4	0	0		
12	C12														

  

NO	KODE	BG	Glomerulus										FGKakoMean	FGKakoMedian	FGKakoModus
			1	2	3	4	5	6	7	8	9	10			
1	F1	1.2886	1	1	0	0	0	1	1	0	0.4	0	0		
2	F2	1.3358	1	1	0	0	0	1	2	0	0.6	1	0		
3	F3	1.4328	1	1	2	2	3	1	2	1	1.6	2	0		
4	F4	1.6961	2	2	1	1	2	1	1	2	1.4	1	1		
5	F5	2.1115	2	2	1	1	1	2	1	1	1.4	1	1		
6	F6	1.8535	3	3	2	2	3	3	2	3	2.6	3	1		
7	F7	1.2467									0	0	3		
8	F8	1.5895	2	2	1	1	3	1	1	1	1.4	0	0		
9	F9	1.2465	3	3	2	2	3	1	2	3	2.4	1	1		
												3	3		

Tubulus Distal																
1	2	3	4	5	6	7	8	9	10	CTDKaKoMean	CTDKaKoMedian	CTDKaKoModus	1	2	3	4
1	1	1	1	1	1	1	2	1	1	1.1	1	1	3	2	3	2
1	1	2	1	1	2	1	1	1	1	1.2	1	1	3	3	3	2
1	1	1	1	2	2	1	1	1	1	1.2	1	1	1	2	3	2
2	1	1	1	1	2	1	1	1	1	1.2	1	1	2	2	2	3
1	2	2	1	1	2	2	1	1	1	1.4	1	1	1	2	2	1
2	2	3	2	2	2	2	3	2	2	2.2	2	2	3	2	3	2
3	3	3	2	2	2	2	3	3	3	2.6	3	3	3	3	3	2
3	3	2	2	2						1.2	1.02	0.822	3	3	3	2
2	2	1	1	2	3	0	1	2	2	1.6	2	2	3	3	2	2
										0	0	0				
2	2	2	2	2	2	2	2	1	3	2	2	2	3	3	2	2
										0	0	0				

TD																
1	2	3	4	5	6	7	8	9	10	CTDKiKoMean	CTDKiKoMedian	CTDKiKoModus	1	2	3	4
1	1	1	1	1	1	0	1	1	1	0.9	1	1	2	2	2	1
1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2
1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2
3	3	3	2	2	2	3	3	2	3	2.6	3	3	3	3	3	3
3	2	2	2	2	2	3	2	2	2	2.2	2	2	3	3	3	2
3	2	2	1	2	2	2	1	3	2	2	2	2	3	2	2	1
3	3	3	2	2	2	3	3	2	2	2.5	3	3	3	3	3	3
1	1	1	1	1						0.5	0.45	0.395	1	2	2	1
2	2	1	1	1	1	1	2	2	1	1.4	1	1	2	2	2	3
										0	0	0				
3	3	3	2	2	2	3	3	3	2	2.6	3	3	3	3	3	2
										0	0	0				

TD																
1	2	3	4	5	6	7	8	9	10	FTDKaKoMean	FTDKaKoMedian	FTDKaKoModus	1	2	3	4
3	3	3	2	2	2	3	3	3	2	2.6	3	3	3	3	2	2
3	3	3	2	2	3	2	2	3	3	2.6	3	3	2	2	3	3
2	3	3	2	2	3	2	3	2	2	2.4	2	2	2	2	3	3
2	2	1	1	2	1	2	1	2	2	1.6	2	2	2	2	2	1
2	2	2	3	2	2	3	2	2	2	2.2	2	2	2	3	3	3
2	2	2	3	3	3	2	3	2	2	2.4	2	2	3	3	3	2
										0	0	0				
3	1	3	1	2	3	2	1	1	3	2	2	2	2	2	3	2
3	3	2	2	2	3	2	2	2	3	2.4	2	2	3	3	3	2

KORTEKS														
TP									Duktus kolekt					
5	6	7	8	9	10	CTPKaKoMean	CTPKaKoMedian	CTPKaKoModus	1	2	3	4	5	6
2	2	2	2	2	2	2.2	2	2	2	1	1	1	1	1
3	2	2	2	2	3	2.5	1	3	1	1	2	2	1	1
3	3	2	3	2	1	2.2	2	2	1	1	1	1	1	1
2	2	2	3	2	2	2.2	2	2	1	1	1	1	0	1
1	1	1	1	2	2	1.4	1	1	1	1	1	1	0	0
2	2	3	3	2	2	2.4	1	2	1	1	1	1	1	1
2	2	3	3	3	2	2.6	3	3	1	1	2	2	2	1
2						1.3	1.13	0.943	1	1	1	2	1	
2	3	3	2	1	3	2.4	1	2	1	2	1	1	1	2
						0	0	0						
2	3	1	2	3	3	2.4	2	2	2	2	2	2	1	2
						0	0	0						

KORTEKS														
TP									Duktus kolekt					
5	6	7	8	9	10	CTPKiKoMean	CTPKiKoMedian	CTPKiKoModus	1	2	3	4	5	6
2	2	2	3	3	2	2.1	2	2	1	1	1	1	1	1
2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
2	2	2	2	2	2	2.1	2	2	1	1	1	1	1	1
2	3	3	3	2	3	2.8	3	3	2	2	1	1	1	1
2	1	3	3	3	3	2.6	3	3	1	1	1	1	1	1
2	3	2	1	2	2	2	2	2	1	1+A	1	2	2	1
2	2	3	3	3	3	2.8	3	3	1	1	2	2	1	2
1						0.7	0.67	0.537	1	1	1	1	1	
2	3	2	2	2	2	2.2	2	2	1	1	1	0	0	0
						0	0	0						
2	2	3	3	3	2	2.6	3	3	2	2	1	1	1	2
						0	0	0						

KORTEKS														
TP						TP			TP					
5	6	7	8	9	10	FTPkaKoMean	FTPkaKoMedian	FTPkaKoModus	1	2	3	4	5	6
3	3	2	3	3	2	2.6	3	3	1	1	2	1	1	1
3	2	2	3	3	3	2.6	3	3	2	1	1	2	1	2
3	2	3	2	3	2	2.5	3	3	2	1	2	2	2	3
1	1	2	1	2	2	1.6	2	2	1	1	1	2	2	1
3	3	2	2	2	2	2.5	3	3	2	2	2	2	2	2
2	3	2	3	3	2	2.6	3	3	2	2	3	2	2	2
						0	0	0						
3	2	3	2	2	2	2.3	2	2	2	2	1	1	1	2
2	2	3	3	2	3	2.6	3	3	2	2	2	3	2	2

ivus (biasanya di medullary rays)							
7	8	9	10	CDKKaKoMean	CDKKaKoMedian	CDKKaKoModus	
1	1	1	1	1.1	1	1	
1	2	2	1	1.4	1	1	
1	1	1	1	1	1	1	
0	1	1	1	0.8	1	1	
1	1	1	1	0.8	1	1	
1	1	1	1	1	1	1	
2	2	2	1	1.6	2	2	
				0.6	0.56	0.516	
1	1	1	1	1.2	1	1	
				0	0	0	
1	2	2	2	1.8	2	2	
				0	0	0	

ivus (biasanya di medullary rays)							
7	8	9	10	CDKKiKoMean	CDKKiKoMedian	CDKKiKoModus	
2	1	1	2	1.2	1	1	
1	1	1	1	1	1	1	
1	1	1	1	1	1	1	
2	1	2	1	1.4	1	1	
1	1	1	1	1	1	1	
2	2	1	1	1.3	1	1	
2	1	1	1	1.4	1	1	
				0.5	0.45	0.395	
1	0	1	1	0.6	1	1	
				0	1	1	
1	2	1	1	1.4	1	1	
				0	0	0	

Duktus kolektivus (biasanya di medullary rays)							
7	8	9	10	FDKKaKoMean	FDKKaKoMedian	FDKKaKoModus	
1	1	1	2	1.2	1	1	
2	1	1	1	1.4	1	1	
1	2	1	2	1.8	2	2	
1	3	1	1	1.4	1	1	
2	2	2	2	2	2	2	
3	2	2	2	2.2	2	2	
				0	0	0	
3	1	1	0	1.4	1	1	
2	2	2	3	2.2	2	2	

Vasa recta	Vena corticomedullary	arteri arcuata	Sel Mesangial										
CVRKaKoMean	CVCKaKoMean	CAAKaKoMean	1	2	3	4	5	6	7	8	9	10	
0	0	0	0	0	0	0	1	0	1	1	0	0	0
0	0	0	0	0	0	1	0	1	1	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0
0	1	1	1	0	0	1	0	0	1	0	0	0	0
1	1	1	1	0	0	1	1	0	1	1	0	0	0
	1	1	1	1	1	1							
0	1	1	1	0	0	0	0	1	0	0	1	0	0
0	1	1	1	0	0	1	1	0	1	1	0	0	0

Vasa recta	Vena corticomedullary	arteri arcuata	Sel Mesangial										
CVRKiKoMean	CVCKiKoMean	CAAKiKoMean	1	2	3	4	5	6	7	8	9	10	
1	1	1	1	1	2	1	0	0	0	0	1	0	0
0	1	1	1	1	1	1	1	1	1	1	1	1	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	1	1	0	0	1	1	0	1	0	1	0	0
1	1	1	1	0	0	0	1	0	0	0	1	0	0
0	1	1	1	0	0	0	0	1	1	0	0	0	0
0	1	1	1	0	0	1	1	1	0	1	1	1	0
1	1	1	1	0	0	0	1	0					
1	1	1	1	0	0	0	0	0	0	0	1	0	0
1	1	1	1	0	0	1	1	0					

Vasa recta	Vena corticomedullary	arteri arcuata											
FVRKaKoMean	FVCKaKoMean	FAAKaKoMean	1	2	3	4	5	6	7	8	9	10	
1	0	0	1	1	0	0	0	0	0	1	1	0	0
1	2	2	1	1	1	0	0	0	1	1	0	1	1
3	2	3	1	1	1	0	0	1	1	0	0	1	1
1	2	2	1	0	0	0	0	0	0	0	1	0	0
2	3	3	1	2	2	1	2	2	2	1	1	1	1
1	2	3	1	1	1	1	1	1	1	1	1	1	1
1	1	1	1	1	1	0	0	0	1	1	0	1	1
2	3	3	3	2	2	1	1	2	2	3	1	1	1

EKSPRESI ENDOTHELIN-A

GINJAL KANAN (CONTROL)

CSMKaKoMean	CSMKaKoMedian	CSMKaKoModus	TD										CTDKaMedMean
			1	2	3	4	5	6	7	8	9	10	
0.3	0	0	2	2	2	2	2	3	3	3	3	3	2.5
0.4	0	0	2	2	3	2	2	2	2	2	3	2	2.2
0	0	0	1	1	1	1	1	1	1	1	1	1	1
0	0	0	2	2	2	3	2	3	2	2	2	2	2.2
0	0	0	2	2	2	1	1	2	2	1	1	2	1.6
0.2	0	0	2	2	2	2	2	2	2	2	2	2	2
0.4	0	0	2	2	2	2	3	2	3	2	2	2	2.2
0.5	0.45	0.395	3	3	2	2	2						1.2
0.2	0	0	3	3	3	2	2	2	3	3	2	2	2.5
0	0	0											0
0.4	0	0	3	3	2	2	2	2	2	3	3	2	2.4
0	0	0											0

GINJAL KIRI (CONTROL)

CSMKiKoMean	CSMKiKoMedian	CSMKiKoModus	TD										CTDKiMedMean
			1	2	3	4	5	6	7	8	9	10	
0.5		1	1	2	3	3	2	1	1	2	1	1	1.7
1		1	2	3	2	2	3	3	3	2	2	2	2.4
0	0	0	1	2	1	1	1	1	1	2	1	1	1.2
0.4		0	3	3	2	2	2	2	3	2	3	2	2.4
0.2		0	2	2	3	3	3	3	2	3	3	2	2.6
0.2		0	2	2	1	1	2	1	2	1	2	2	1.6
0.6	1	1	3	3	3	2	2	2	3	2	3	3	2.6
0.1	0.11	0.121	1	1	1	1	1						0.5
0.1		0	2	2	3	3	3	3	3	2	3	2	2.6
0	0	0											0
0.2		0	2	2	3	3	2	3	2	3	2	2	2.4
0	0	0											0

GINJAL KANAN (HIGH FAT DIET)

Sel Mesangial	Sel Mesangial	Sel Mesangial	TD										FTDKaMedMean
FSMKaKoMean	FSMKaKoMedian	FSMKaKoModus	1	2	3	4	5	6	7	8	9	10	
0.4	0	0	2	2	2	3	1	3	2	2	1	2	2
0.6	1	1	3	3	3	2	2	3	2	3	3	2	2.6
0.6		1	3	3	2	2	2	2	2	3	3	2	2.4
0.2		0	2	2	2	2	2	2	2	2	2	2	2
1.5		2	2	2	3	3	2	2	3	3	2	2	2.4
1		1	3	2	3	2	2	2	3	2	2	3	2.4
0	0	0											0
0.6		1	2	2	1	2	2	2	1	2	2	2	1.8
1.8		2	3	3	2	2	3	3	3	1	3	3	2.6

10	F10	1.592	2	2	1	1	1	3	1	1	1	1	1	1	1.4	1	1
11	F11														0	0	0
12	F12	1.5066	2	3	3	3	2	2	2	2	3	3		2.5	3	3	
NO	KODE	BG	Glomerulus										FGKiKoMean	FGKiKoMedian	FGKiKoModus		
			1	2	3	4	5	6	7	8	9	10					
1	F1	1.2805	1	1	0	0	1	1	1	1	0	0		0.6	0	1	
2	F2	1.3065	0	0	0	0	0	0	0	0	0	0		0	0	0	
3	F3	1.3094	1	2	1	2	1	2	1	2	1	1		1.4	1	1	
4	F4	1.5699	2	2	1	1	1	2	1	1	1	2		1.4	1	1	
5	F5	1.9509	2	2	1	1	1	2	1	1	1	2		1.4	3	1	
6	F6	1.638	2	1	1	1	0	0	1	1	1	2		1	2	1	
7	F7	1.1817												0	0	0	
8	F8	1.5097	1	1	2	2	1	2	1	2	1	1		1.4	2	1	
9	F9	1.1985	3	2	2	1	1	2	3	2	1	1		1.8	2	2	
10	F10	1.568	2	2	1	1	1	1	1	2	2	1		1.4	1	1	
11	F11													0	0	0	
12	F12	1.2553	3	3	2	2	2	2	2	3	2	3		2.4	2	2	

KETERANGAN :

BG : BERAT GINJAL

G : Glomerulus

TP : Tubulus Convuluted Proksimal = with vili, sel sedikit, sel lebih besar

TD : Tubulus convuluted distal= tidak ada brush border, sel lebih kecil, sel lebih banyak, sitoplasma pale

LH : Loop of Henle

V : vasa vascular medulla

duktus kolektivus cari di medullary ray (batas dengan medula)

arteri arkuata dan vena baku dekat di juxtamedullary junction)

sesuai teori:

ETA dan ET1 meningkat pada kelainan ginjal

ETB bekerja dengan menghilangkan ET1 dari plasma, berarti pada penyakit ginjal,,,,ETB terekspresi sedikit

duktus kolektivus ada di korteks dan medula

cari arteri arkuata

vasa recta ???

2	2	3	2	2	3	2	2	2	2	2	2.2	2	2	3	3	3	2
											0	0	0				
3	3	3	2	2	2	3	3	3	2		2.6	3	3	2	2	2	2

TD										FTDKiKoMean	FTDKiKoMean	FTDKiKoModus	1	2	3	4	
2	2	3	2	3	3	2	3	2	2	2.4	2	2	2	2	2	3	3
1	1	2	2	1	1	1	1	2	2	1.4	1	1	2	2	1	1	
3	3	2	2	2	3	2	3	2	2	2.4	2	2	2	2	3	3	
3	3	3	2	2	2	2	3	3	3	2.6	3	3	2	2	3	1	
3	3	2	2	2	2	2	3	3	2	2.4	2	2	3	2	3	2	
2	2	1	1	2	1	1	2	2	2	1.6	2	2	3	3	2	2	
										0	0	0					
2	1	3	2	2	3	1	2	2	2	2	2	2	3	2	2	2	
3	2	1	1	2	2	1	1	2	3	1.8	2	2	3	2	2	1	
2	2	3	2	2	2	2	3	2	2	2.2	2	2	3	3	2	2	
										0	0	0					
2	2	3	3	3	2	3	3	2	3	2.6	3	3	3	3	2	2	

2	2	3	2	3	3	2.6	3	3	2	2	2	2	2	2
						0	0	0						
2	2	3	2	2	3	2.2	2	2	2	2	3	1	3	3

**KORTEKS**

TP										Duktus kolekt					
5	6	7	8	9	10	FTPkiKoMean	FTPkiKoMedian	FTPkiKoModus	1	2	3	4	5	6	
2	2	2	2	3	3	2.4	2	2	1	1	1	1	1	1	
1	2	1	1	1	2	1.4	1	1	1	1	1	1	1	1	
3	3	2	3	3	2	2.6	3	3	1	1	1	1	1	1	
1	2	3	2	1	1	1.8	2	2	2	2	1	1	1	1	
2	3	3	2	2	2	2.4	2	2	2	2	1	1	1	2	
2	2	3	2	3	2	2.4	2	2	2	2	2	1	1	2	
						0	0	0							
3	3	3	2	2	2	2.4	2	2	2	1	1	1	1	1	
1	3	2	1	2	1	1.8	2	2	2	2	1	2	2	2	
2	3	2	3	2	2	2.4	2	2	2	3	2	2	2	2	
						0	0	0							
3	3	3	2	3	2	2.6	3	3	2	2	3	1	2	3	

2	2	2	2	2	2
				0	0
3	1	2	2	2.2	2

**ivus (biasanya di medullary rays)**

7	8	9	10	FDKKiKoMean	FDKKiKoMedian	FDKKiKoModus
1	1	1	1	1	1	1
1	1	1	1	1	1	1
1	1	1	1	1	1	1
2	2	1	1	1.4	1	1
2	1	1	1	1.4	1	1
3	1	1	1	1.6	2	2
				0	0	0
1	2	1	1	1.2	1	1
3	1	2	1	1.8	2	2
2	2	2	3	2.2	2	2
				0	0	0
2	2	2	3	2.2	2	2



